Compare · CERS vs PDD
CERS vs PDD
Side-by-side comparison of Cerus Corporation (CERS) and PDD Holdings Inc. (PDD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CERS and PDD operate in EDP Services (Technology), so they compete in similar markets.
- PDD is the larger of the two at $117.60B, about 225.7x CERS ($521.0M).
- Over the past year, CERS is up 76.0% and PDD is down 18.4% - CERS leads by 94.4 points.
- CERS has been more active in the news (12 items in the past 4 weeks vs 5 for PDD).
- PDD has more recent analyst coverage (25 ratings vs 4 for CERS).
- Company
- Cerus Corporation
- PDD Holdings Inc.
- Price
- $2.60-0.38%
- $82.89+0.35%
- Market cap
- $521.0M
- $117.60B
- 1M return
- -0.38%
- -15.99%
- 1Y return
- +76.01%
- -18.40%
- Industry
- EDP Services
- EDP Services
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1997
- 2018
- News (4w)
- 12
- 5
- Recent ratings
- 4
- 25
Cerus Corporation
Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation has collaboration with LifeSouth Community Blood Centers to manufacture INTERCEPT Fibrinogen Complex. The company was incorporated in 1991 and is headquartered in Concord, California.
PDD Holdings Inc.
Pinduoduo Inc., through its subsidiaries, operates an e-commerce platform in the People's Republic of China. It operates Pinduoduo, a mobile platform that offers a range of products, including apparel, shoes, bags, mother and childcare products, food and beverage, fresh produce, electronic appliances, furniture and household goods, cosmetics and other personal care items, sports and fitness items, and auto accessories. The company was formerly known as Walnut Street Group Holding Limited and changed its name to Pinduoduo Inc. in July 2018. Pinduoduo Inc. was incorporated in 2015 and is headquartered in Shanghai, the People's Republic of China.
Latest CERS
- Cerus Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation
- Cerus Corporation Closes New Debt Facility of Up to $110 Million
- Cerus Corporation filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders
- Director Lucena Ann was granted 60,000 shares, increasing direct ownership by 35% to 232,284 units (SEC Form 4)
- Director Bjerkholt Eric was granted 60,000 shares, increasing direct ownership by 27% to 282,133 units (SEC Form 4)
- Director Nachtsheim Jami K was granted 60,000 shares, increasing direct ownership by 29% to 268,362 units (SEC Form 4)
- Chief Operating Officer Jayaraman Vivek K sold $50,001 worth of shares (16,667 units at $3.00) as part of a pre-agreed trading plan, decreasing direct ownership by 1.00% to 1,656,707 units (SEC Form 4)
- Director Witney Frank was granted 60,000 shares, increasing direct ownership by 21% to 340,059 units (SEC Form 4)
- Director Gregory Dean A. was granted 60,000 shares, increasing direct ownership by 69% to 146,725 units (SEC Form 4)
- Director Shan Hua was granted 60,000 shares, increasing direct ownership by 45% to 192,386 units (SEC Form 4)
Latest PDD
- PDD Holdings downgraded by Macquarie with a new price target
- PDD Holdings downgraded by Barclays with a new price target
- SEC Form 6-K filed by PDD Holdings Inc.
- PDD Holdings Announces First Quarter 2026 Unaudited Financial Results
- PDD Holdings to Report First Quarter 2026 Unaudited Financial Results on May 27, 2026
- SEC Form 20-F filed by PDD Holdings Inc.
- PDD Holdings upgraded by Arete with a new price target
- SEC Form 4 filed by Rietjens Ivonne Mcm
- SEC Form 4 filed by Kam Anthony Ping Leung
- PDD Holdings upgraded by Nomura with a new price target